Sei Investments Co. Has $2.80 Million Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Sei Investments Co. grew its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 58.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 109,557 shares of the biopharmaceutical company's stock after buying an additional 40,271 shares during the period. Sei Investments Co.'s holdings in Royalty Pharma were worth $2,795,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in RPRX. Swedbank AB boosted its position in shares of Royalty Pharma by 10.3% in the 4th quarter. Swedbank AB now owns 12,164,170 shares of the biopharmaceutical company's stock valued at $310,308,000 after purchasing an additional 1,136,800 shares during the period. State Street Corp lifted its holdings in shares of Royalty Pharma by 0.3% in the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company's stock valued at $269,215,000 after buying an additional 29,451 shares during the period. Geode Capital Management LLC boosted its position in shares of Royalty Pharma by 6.1% during the 3rd quarter. Geode Capital Management LLC now owns 7,265,786 shares of the biopharmaceutical company's stock worth $205,562,000 after purchasing an additional 417,490 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Royalty Pharma by 4.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock worth $79,888,000 after buying an additional 130,025 shares during the period. Finally, Two Sigma Advisers LP grew its holdings in shares of Royalty Pharma by 44.7% in the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company's stock worth $85,809,000 after acquiring an additional 936,900 shares during the period. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Up 4.6 %

Shares of RPRX stock traded up $1.42 on Wednesday, hitting $32.27. The stock had a trading volume of 7,300,464 shares, compared to its average volume of 3,214,959. The stock's 50 day moving average is $32.49 and its 200-day moving average is $29.08. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The firm has a market capitalization of $18.60 billion, a price-to-earnings ratio of 22.26, a P/E/G ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 52-week low of $24.05 and a 52-week high of $34.20.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. As a group, research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current year.

Royalty Pharma Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, March 10th. Investors of record on Friday, February 21st were given a dividend of $0.22 per share. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.73%. The ex-dividend date was Friday, February 21st. Royalty Pharma's dividend payout ratio is currently 60.69%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of analyst reports. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. TD Cowen upgraded Royalty Pharma to a "strong-buy" rating in a report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Royalty Pharma has an average rating of "Buy" and a consensus price target of $41.60.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.